Characterization of TP53 and PI3K signaling pathways as molecular targets in gynecologic malignancies

  • J Obstet Gynaecol Res. 2016 Jul;42(7):757-62. doi: 10.1111/jog.13018.
Katsutoshi Oda  1 ,  Yuji Ikeda  1 ,  Tomoko Kashiyama  1 ,  Aki Miyasaka  1 ,  Kanako Inaba  1 ,  Tomohiko Fukuda  1 ,  Kayo Asada  1 ,  Kenbun Sone  1 ,  Osamu Wada-Hiraike  1 ,  Kei Kawana  1 ,  Yutaka Osuga  1 ,  Tomoyuki Fujii  1
Affiliations
  • 1. Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
PMID: 27094348 DOI: 10.1111/jog.13018
Abstract

Recent developments in genomic analysis have unveiled the key signaling pathways in human Cancer. However, only a limited number of molecular-targeted drugs are applicable for clinical use in gynecologic malignancies. TP53 signaling and phosphatidylinositol 3 kinase pathways are frequently mutated in Cancer, and have received much attention as molecular targets in human cancers. In this review, we mainly focus on the functions of these pathways, and discuss the molecular-targeted drugs under clinical trials. The molecular-targeted drugs described in this review include dual phosphatidylinositol 3 kinase/mTOR inhibitors (NVP-BEZ235, DS-7423, SAR245409), an mTOR Inhibitor (everolimus), an MEK Inhibitor (pimasertib), an Autophagy inhibitor (chloroquine), a cyclin-dependent kinases 4/6 inhibitor (PD0332991), and a poly (ADP-ribose) polymerase inhibitor (olaparib).

Keywords
TP53; endometrial cancer; molecular target therapy; ovarian clear cell carcinoma; phosphatidylinositol 3 kinase.
Products